by Raynovich Rod | Jul 6, 2012 | BIOgraph, Clinical Diagnostics and Tools
Vermillion Stock Outperforms BG Medicine Since April 3 On 4/3/12 we posted the biomarker challenge featuring two emerging public companies that have approved diagnostic products. In a few weeks we will have Q2 financial data on these two companies BG Medicine (BGMD)...
by Rod Raynovich | May 19, 2011 | 2024-25 Life Science Portfolios, BIOgraph
But ThermoFisher (TMO $65.12) is Up 3.78% on Volume of 3.2M Shares GenProbe (GPRO $84.10) down 2.9% sold off some of of the speculative gains from yesterday after ThermoFisherScientific (TMO) announced it was buying Phadia, a privately held Swedish diagnostic Company...
by Rod Raynovich | May 11, 2011 | BIOgraph, Macro, Reading List
Relative Safety in Healthcare Stocks Today’s sell-off in the energy complex with the back-drop of a U.S. slow growth scenario plus the Euro being vulnerable due to Greece and Ireland has spooked the overall market. All the major indices are down over 1% with the...
by Rod Raynovich | May 10, 2011 | 2024-25 Life Science Portfolios, BIOgraph
Deals Are Bullish for the Market Yesterday’s Alkermes (ALKS) deal with Elan (ELN) supports the major M&A trend in the life science market. Timing is everything in a hot market. The rationale for the current M&A activity is: technologies and pipeline fit...
by Rod Raynovich | Mar 28, 2011 | BIOgraph
Ariad (ARIA $7.24 up 4.3%) continues to roll on today on heavy volume up 17% over 5 days on speculation, news and upgrades with strong expectations for their chronic myeloid leukemia drug ponatinib. Articles from Motley Fool, Seeking Alpha and The Street.com have...
by Rod Raynovich | Mar 11, 2011 | BIOgraph, Reading List
Hot biomedical concepts: Software, mobile communications, ophthalmology,antibiotics,epilepsy,surgery,cancer, and publishing. On Thursday March 9 The Wall Street Journal published an excellent review of the Top 50 start-ups and the money raised.The leaders were...
by Rod Raynovich | Nov 8, 2010 | 2024-25 Life Science Portfolios, BIOgraph
Immucor (BLUD) stock was up 5.7% to $18.91 on news that the DOJ closed its anti-trust investigation. The stock hit a low in early October when it slashed guidance due to lower utility of blood transfusion services.The Company is a leader in automated blood...
by Rod Raynovich | Aug 17, 2010 | 2024-25 Life Science Portfolios, BIOgraph
The IPO market is setting up for continued investor interest in the biotech sector. Two high profile genomics companies,Complete Genomics and Pacific Biosciences, have filed S-1 Registration Statements with plans to go public in the fourth quarter around the time when...
by Rod Raynovich | Jun 14, 2010 | RAG
Genomics and Medicine: transformative therapies are coming but diagnostic breakthroughs will lead the way Ten years after the start of the Human Genome Project we have learned a lot about the links between genetics and disease but few direct cures have emerged. The...
by Rod Raynovich | May 12, 2010 | BIOgraph
Genotyping on a Fast Track Direct to Consumer Pathway Genomics is offering a “Health Kit” that reports your genetic risk for 70 diseases such as Cancer,Cardiovascular Disease,RA,and Diabetes. Disease carrier status is included as well as potential genetic...
